Table 3 Recommended composite disease activity assessments and prognostic assessment to guide treatment
From: A systematic review of guidelines for managing rheumatoid arthritis
Guideline | Composite Disease Activity Assessments | Prognostic Assessments | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
PAS | RAPID3 | CDAI | SDAI | DAS28 | RF | ACPA | X-ray Erosions | Poor Function | Extra-Articular Disease | |
1. American [14] | Yes | Yes | Yes | Yes | Yes | Â | Â | Â | Â | Â |
2. APLAR [15] | – | – | Yes | Yes | Yes | Yes | Yes | Yes |  |  |
3. Australian [16] | – | – | – | – | – | Yes | Yes | Yes |  |  |
4. Brazilian [17] | – | – | Yes | Yes | Yes | Yes | Yes | Yes |  |  |
5. British Columbia [18] | – | – | – | – | – |  | Yes | Yes |  |  |
6. British Society For Rheumatology: Established [19] | – | – | – | – | – |  |  |  |  |  |
7. British Society For Rheumatology: Early [20] | – | – | – | – | – |  |  |  |  |  |
8. Canadian [21] | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
9. EULAR [22] | Â | Â | Yes | Yes | Yes | Yes | Yes | Yes | Â | Â |
10. French [23] | Â | Â | Yes | Yes | Yes | Yes | Yes | Yes | Â | Â |
11. German [24] | – | – | – | – | Yes | Yes | Yes | Yes |  |  |
12. Hong Kong [25] | – | – | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
13. Indian [26] | – | – | Yes | Yes | Yes | Yes | Yes | Yes |  | Yes |
14. Latin American [27] | – | – | – | – | Yes | Yes | Yes | Yes | Yes | Yes |
15. Mexican [28] | Â | Â | Yes | Yes | Yes | Yes | Yes | Â | Â | Yes |
16. England [29] | – | – | – | – | Yes |  |  |  |  |  |
17. Scotland [30] | – | – | Yes | Yes | Yes |  |  |  |  |  |
18. South African [31] | – | – | – | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
19. Spanish [32] | – | – | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
20. Swedish [33] | – | – | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
21. Treat to Target [34] | – | – | Yes | Yes | Yes |  |  |  |  |  |
22. Turkish [35] | – | – | – | – | Yes |  | Yes | Yes | Yes |  |